Thanks again for the work you have put into this. Commentary from the “Scientists” out there is almost always of a negative and oppositional view, the fact that there is none speaks volumes.
Have you managed to place any of your concepts in front of Medicenna's management? Are they aware of this?
I've held shares since 2018. I'm growing increasingly concerned with the inability to even get a partnership going let alone attract institutional interest. (I realize it OTC)
They are under one year from having to dilute current shareholders. From your research, things will become very expensive, very soon.
Hi CC - thanks for reading! Medicenna’s management is indeed aware of my work and the broader research I’ve been publishing, though I operate independently as a shareholder and "analyst". I don’t have any official affiliation, nor am I compensated — this has always been an outside-in effort to contextualize MDNA11’s science and strategy for investors, researchers, interested readers, etc.
My perspective on the institutional interest point is shared relative to MDNA55, however the RA Capital Management raise was very impressive. Dr. Merchant - IMHO - has no issues raising capital. It isn’t about a lack of compelling data — the responses across CRC, PDAC, EC, and viral tumors speak for themselves — but more about market structure, suppression dynamics, and a lag in recognizing first-in-class platforms until catalysts (like trial expansions, KOLs, or partnerships) occur or break through.
Another issue it seems to me on this front is that institutional investors don’t accumulate positions through OTC trading. The liquidity is too thin, the optics are poor, and compliance teams typically block that route. Instead, they tend to wait for uplistings, secondary offerings, or direct placements...all things that screw us the long term shareholder. The only thing I can say to assuage you on that front, is Dr. Merchant is the biggest long term shareholder so what he does to the goose, he does to the gander. And how he addresses that is a big question mark right now. No two ways about it.
I'll be posting another article shortly that takes a step back and explains how this whole project (PRISM-11) came to be — not just MDNA11’s valuation arc, but the process of structuring the research and how it differs from casual coverage. My aim is to make the underlying thesis unmissable: MDNA11’s MOA, monitoring edge, and salvage data together represent an asset whose value will eventually demand institutional recognition, regardless of short-term headwinds. So you will get as transparent a view into this as I can make it without giving up my own trade secrets.
I had hoped to get more engagement from folks on X 'challenging me' / PRISM-11 on our research and conclusions, but it hasn't happened. As @michael007here on X generously defended me on one thread: "...until I see your scientific response to everything he has said I will figure his analysis is way above your head, it’s funny that I don’t [see] any responses from ANYONE on a scientific basis..."
I'll end my response with: I do have some interesting subscribers though. And, no there won't be details from me.
Thanks for the detailed response. I would be remiss if I didn't say that I certainly appreciate your continuing efforts and like you, perplexed why you haven't been engaged more? I will pledge my support once a price/value inflection point is reached.
Lastly, Sanofi's acquisition of Synthorx for $2.5 Billion in 2019 soured the entire IL-2 space. When I read your work, I entertain the thought that Medicenna can sweeten it once more.
Hey Ed, thank you. Appreciate it! I wish I had the answer in terms of ‘when will this get noticed.’ Frankly, part of why I am doing what I am doing is to drive more notice because very few ‘official analysts’ and research publishers are providing the appropriate coverage. I think we all at times get hung up on the psychology side of it (i.e. look at the stock price oh no!!!). I divorced myself from that once I came to my conclusion, assisted by knowledgeable people I trust, that the stock is being manipulated - and not just Medicenna. It’s endemic across small and micro caps. So, I only focus on what I can prove and research. As long as that stays true, I’ll maintain my position.
David: Assuming you are right, then we come back to my original point months ago, that we have to figure a way to get this to the right analysts. That is why I asked about Fahar Merchant, but I can’t believe he is not trying to get the word out besides his excellent presentations. I am as frustrated as you, but you have the advantage of continuing to publish your excellent articles!
Thanks again for the work you have put into this. Commentary from the “Scientists” out there is almost always of a negative and oppositional view, the fact that there is none speaks volumes.
Keep cookin’!
My pleasure Frank. Appreciate it! Today will be a blue light special day. A lot of bits and pieces to push out. Some interesting nuggets (I hope)…
Hi David,
Have you managed to place any of your concepts in front of Medicenna's management? Are they aware of this?
I've held shares since 2018. I'm growing increasingly concerned with the inability to even get a partnership going let alone attract institutional interest. (I realize it OTC)
They are under one year from having to dilute current shareholders. From your research, things will become very expensive, very soon.
Regards
CC
Hi CC - thanks for reading! Medicenna’s management is indeed aware of my work and the broader research I’ve been publishing, though I operate independently as a shareholder and "analyst". I don’t have any official affiliation, nor am I compensated — this has always been an outside-in effort to contextualize MDNA11’s science and strategy for investors, researchers, interested readers, etc.
My perspective on the institutional interest point is shared relative to MDNA55, however the RA Capital Management raise was very impressive. Dr. Merchant - IMHO - has no issues raising capital. It isn’t about a lack of compelling data — the responses across CRC, PDAC, EC, and viral tumors speak for themselves — but more about market structure, suppression dynamics, and a lag in recognizing first-in-class platforms until catalysts (like trial expansions, KOLs, or partnerships) occur or break through.
Another issue it seems to me on this front is that institutional investors don’t accumulate positions through OTC trading. The liquidity is too thin, the optics are poor, and compliance teams typically block that route. Instead, they tend to wait for uplistings, secondary offerings, or direct placements...all things that screw us the long term shareholder. The only thing I can say to assuage you on that front, is Dr. Merchant is the biggest long term shareholder so what he does to the goose, he does to the gander. And how he addresses that is a big question mark right now. No two ways about it.
I'll be posting another article shortly that takes a step back and explains how this whole project (PRISM-11) came to be — not just MDNA11’s valuation arc, but the process of structuring the research and how it differs from casual coverage. My aim is to make the underlying thesis unmissable: MDNA11’s MOA, monitoring edge, and salvage data together represent an asset whose value will eventually demand institutional recognition, regardless of short-term headwinds. So you will get as transparent a view into this as I can make it without giving up my own trade secrets.
I had hoped to get more engagement from folks on X 'challenging me' / PRISM-11 on our research and conclusions, but it hasn't happened. As @michael007here on X generously defended me on one thread: "...until I see your scientific response to everything he has said I will figure his analysis is way above your head, it’s funny that I don’t [see] any responses from ANYONE on a scientific basis..."
I'll end my response with: I do have some interesting subscribers though. And, no there won't be details from me.
Thanks for the detailed response. I would be remiss if I didn't say that I certainly appreciate your continuing efforts and like you, perplexed why you haven't been engaged more? I will pledge my support once a price/value inflection point is reached.
Lastly, Sanofi's acquisition of Synthorx for $2.5 Billion in 2019 soured the entire IL-2 space. When I read your work, I entertain the thought that Medicenna can sweeten it once more.
David: Again, another tremendous article!
When will this get noticed?
What is holding it back?
What more are they waiting for?
Incredible!
Ed
Hey Ed, thank you. Appreciate it! I wish I had the answer in terms of ‘when will this get noticed.’ Frankly, part of why I am doing what I am doing is to drive more notice because very few ‘official analysts’ and research publishers are providing the appropriate coverage. I think we all at times get hung up on the psychology side of it (i.e. look at the stock price oh no!!!). I divorced myself from that once I came to my conclusion, assisted by knowledgeable people I trust, that the stock is being manipulated - and not just Medicenna. It’s endemic across small and micro caps. So, I only focus on what I can prove and research. As long as that stays true, I’ll maintain my position.
David: Assuming you are right, then we come back to my original point months ago, that we have to figure a way to get this to the right analysts. That is why I asked about Fahar Merchant, but I can’t believe he is not trying to get the word out besides his excellent presentations. I am as frustrated as you, but you have the advantage of continuing to publish your excellent articles!
Ed